PRLD Prelude Therapeutics Inc.: רווח נקי למניה ב-12 החודשים האחרונים

The current financial health of Prelude Therapeutics (PRLD) is based exclusively on investments, as the company has not yet developed any profitable products. The historical price action of EPS (TTM) is recorded at 55.50. The business model relies on external contractors for testing and production, which creates dependency risks. Growth prospects are determined by the safety of new molecules and the ability to fund development until the sales stage.
PRLD (Prelude Therapeutics Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

Developing costly proprietary molecules for lymphatic system cancer therapy requires colossal capital, which directly impacts the net income of Prelude Therapeutics (PRLD). The current YoY EPS change on a rolling 12-month basis at 55.50 reflects the earnings per share dynamics, allowing investors to assess the sustainability of the business model and determine whether the asset's market value is justified by current yield rates.